Form 4: Nuvectis Pharma Director Kenneth Hoberman Granted 30,000 Restricted Shares

Nuvectis Pharma, Inc. Director Kenneth Hoberman was granted 30,000 shares of restricted common stock, increasing his total beneficial ownership to 133,140 shares, with vesting tied to continued board service.

Summary

• Kenneth Hoberman, a Director of Nuvectis Pharma, Inc. (NVCT), acquired 30,000 shares of common stock.
• The transaction occurred on June 12, 2025.
• These shares were acquired at a price of $0, indicating a grant of restricted stock.
• Following this transaction, Mr. Hoberman's total beneficial ownership in Nuvectis Pharma, Inc. is 133,140 shares.
• The 30,000 restricted shares will vest in equal annual installments over three years, contingent on Mr. Hoberman's continued service on the Company's Board of Directors.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a director is a positive sign of alignment and commitment, though it is a routine compensation event rather than a significant operational or financial announcement that would drastically alter the company's outlook.

Positives

• The grant of restricted stock to a director aligns his interests with shareholders, incentivizing long-term commitment to the company's performance.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects and strategic direction.

Risks

• The vesting of the 30,000 restricted shares is contingent upon Mr. Hoberman's continued service on the Board of Directors; if his service ceases, the unvested shares may be forfeited.

Future Outlook

The vesting schedule for the restricted shares implies a continued commitment from Director Kenneth Hoberman to serve on the Board for at least the next three years, aligning his long-term interests with the company's performance.

Industry Context

Granting restricted stock to directors is a common and standard practice across various industries, including biotechnology and pharmaceuticals, to align the interests of board members with long-term shareholder value creation and to incentivize retention of key talent. This practice is particularly prevalent in growth-oriented companies like Nuvectis Pharma, Inc. (NVCT).

Comparison to Industry Standards

• This equity compensation practice for board members is consistent with global benchmarks for corporate governance and executive compensation.
• Companies such as Moderna (MRNA), BioNTech (BNTX), and other biotech firms frequently utilize similar long-term incentive structures for their directors, often involving restricted stock units or options that vest over several years.
• The specific number of shares granted would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry sector to ensure competitive and appropriate compensation.

Related Party Transactions

• Grant of 30,000 restricted common shares to Kenneth Hoberman, a Director of Nuvectis Pharma, Inc., as part of his compensation for board service, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant increases the alignment of a director's financial interests with long-term shareholder value creation, potentially fostering more shareholder-centric decision-making.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued service of Kenneth Hoberman on the Board of Directors for the restricted shares to vest.
• Annual vesting installments of the 30,000 restricted shares over the next three years, beginning on the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Nuvectis Pharma, NVCT, Kenneth Hoberman, Form 4, Insider Trading, Restricted Stock, Director Compensation, Equity Grant, Stock Vesting